Johnson & Johnson is pumping more money into heart care with a roughly $13 billion deal for Shockwave Medical, which specializes in technology that helps open clogged arteries.
The health care giant said Friday that it will spend $335 in cash for each share of Shockwave. The total deal value includes cash acquired.
The deal has already been approved by the boards of directors from both companies.
Founded in 2009, Shockwave focuses on intravascular lithotripsy technology that uses sonic pressure waves to crack calcium lesions in arteries and restore blood flow. It’s similar to a technique used to break up kidney stones. The soundwave emitters are placed inside angioplasty catheters to reach the calcified areas of the artery.
Shockwave’s technology is used to treat coronary artery and peripheral artery disease.
The company’s revenue jumped 49% last year to $730 million.
A look at how jury selection will work in Donald Trump's first criminal trial
Sri Lanka to join Regional Comprehensive Economic Partnership: president
A look at how jury selection will work in Donald Trump's first criminal trial
Germany's foreign minister visits Kyiv as Ukraine battles to hold off a Russian offensive
China, South Africa see broad cooperation prospects in automotive industry
Sudan: Aid groups warn of mass death from hunger
Qinghai province activates development potential via featured industries
Defending champion South Carolina to open season in Las Vegas against Michigan
New productive forces play key role in growth
Red Lobster seeks bankruptcy protection after closing some restaurants
Stefan Frei makes 300th regular season appearance for Sounders in 0